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Abstract
The Workshop associated with the 27th Annual Meeting of the Society for Immunotherapy of Cancer (SITC),
North Bethesda, MD, October 24-25, 2012 focused on targeting the tumor microenvironment as part of an
integrative approach to immune-based cancer therapy.
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Established tumors are complex, heterogeneous masses
composed of malignant cells admixed with a variety of
non-transformed host cells, including stromal cells, endo-
thelial cells, and immune cells. This elaborate web of di-
verse cell types fosters malignant tumor cell interactions
with the tumor associated vasculature and fibroblasts as
well as a variety of immune cells in support of tumor
growth, invasion, and metastasis. The importance of these
dynamic cellular interactions in the development of cancer
has stimulated strong interest in evaluating components of
the tumor microenvironment as targets for cancer therapy.
Multiple lines of research aim to dissect the tumor micro-
environment to gain insight into cancer prognosis and
treatment selection, as well as to further understand the
mechanisms that drive immune-based tumor rejection.
To support these efforts, the Society for Immunotherapy
of Cancer (SITC) held a workshop focused on targeting
the tumor microenvironment as part of an integrative
approach to immune-based cancer therapy. SITC is a
non-profit group of medical professionals established in
1984 to facilitate the exchange and promotion of scien-
tific information about the promise and breakthroughs
of immunotherapy for cancer patients. Society members
include a constituency of nearly 600 clinical and basic
scientists from around the world working in academia,
industry, and governmental regulatory agencies. SITC’s
members represent 17 medical specialties and are engaged
in research and treatment of most types of cancer. The
Society was founded on the belief that new immune-based
treatments would continue to complement traditional can-
cer treatments and move into the mainstream in the fight
against cancer. To aid in this effort, SITC provides a venue
to facilitate the discussion of current clinical trial results
and methodologies, as well as means to collaborate on
new initiatives in tumor immunology and cancer immuno-
therapy with the ultimate goal of improving cancer patient
outcomes.
The following themes were selected for the focus of the
2012 SITC workshop: (1) cellular and molecular interac-
tions within the tumor microenvironment that impact
the activities of innate and antigen-specific immune cells;
(2) manipulation of these interactions to remodel the tumor
microenvironment and promote tumor regression (3) cur-
rent and future combination cancer immunotherapies for
clinical use that actively target components of the tumor
microenvironment to provoke lasting tumor immunity and
improve patient outcomes; and (4) the tumor Immunoscore
as a new indicator of prognosis, and predictive marker of
response to cancer therapy.
Immunoregulatory components of the tumor
microenvironment
The host antitumor immune response can sculpt tumor
growth, invasion, and metastasis in a variety of ways.
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The prevention of immune cell access into the tumor,
the accumulation of inhibitory FoxP3+ regulatory T cells
(Treg) and/or myeloid-derived suppressor cells (MDSCs),
the activation of negative immunoregulatory pathways,
and the dysregulation of effector T cells are all mecha-
nisms by which tumors evade the host immune system.
Notably, the presence of large numbers of tumor infiltrat-
ing T lymphocytes (TILs) has been reported to be an indi-
cator of good prognosis in multiple solid tumors [1-5].
Therefore, it is not surprising that physically preventing
effector CD8+ T cell infiltration or inhibiting their activity
once they gain access to the tumor might be a means by
which tumors protect themselves from immune attack,
enabling them to persist within the host.
Dr. George Coukos presented an elegant characterization
of the immunobiology of ovarian cancers. Almost 50% of
ovarian cancer patients lack CD3+ TILs within nests of
tumor epithelial cells, despite the presence of CD3+ TILs
within the host stroma [4]. The absence of intratumoral
TILs is correlated with decreased survival in these patients.
Tumor endothelial cells (TECs) present at the blood-tumor
barrier act as gatekeepers, regulating the homing, adhesion
and transendothelial migration of lymphocytes into the
tumor [6]. Dr. Coukos and his team further studied the
dynamic interactions between tumor cells, endothelial
cells and T cells in ovarian cancer. Analysis of ovarian
tumors by immuohistochemistry (IHC) detected an over-
expression of endothelin type B receptor (ETBR) by the
tumor-associated vasculature and stromal cells within
ovarian tumors with decreased CD3+ TIL. ETBR expres-
sion was associated with the loss of T cell infiltration
into tumors and down regulation of Intercellular Adhe-
sion Molecule-1 (ICAM-1 or CD54) expression, a T cell
adhesion molecule expressed by endothelial cells. In an
ID8 ovarian cancer and a human papillomavirus E6/E7
transformed model (TC-1), blockade of ETBR enhanced
T cell infiltration and augmented vaccine-induced tumor
regression without an increase in systemic T cell number
or activity [6]. In addition, many TECs express Fas-
ligand (FasL or CD95L), and induce the death of Fas-
expressing T cells attempting to gain access to the tumor.
Thus, TECs can create a protective barrier to block or dis-
rupt transendothelial T cell migration and survival within
the tumor microenvironment [6].
If high levels of TILs can be associated with better
progression-free and overall survival, then why does the
presence of TILs not always result in tumor rejection?
Part of the reason is that both innate and adaptive
immune cells that gain access to the tumor site can
contribute to disease progression. They do this by cor-
rupting the inherent protective inflammatory response
mounted against the tumor to promote immune evasion.
Alterations in tumor cell biology can lead to decreased
susceptibility to killing, and alterations in antigen presenting
cells can lead to faulty T cell priming and promote T cell
dysfunction. Both the induction of suppressive cyto-
kines and the expression of negative immunomodula-
tory molecules within the tumor microenvironment can
dampen immune responses. High levels of interleukin-
10 (IL-10) and/or transforming growth factor-β (TGF-β),
the expression of FAS ligand (FASL), programmed cell
death ligand-1 (PDL-1 or CD274) and programmed cell
death ligand-2 (PDL-2), and the expression of immuno-
modulatory enzymes like indoleamine 2,3-dioxygenase,
(IDO), arginase (ARG) or inducible nitric-oxide synthase
(iNOS) can inhibit tumor immunity [7]. The major pro-
ducers of these immunoregulatory molecules include
toleragenic dendritic cells (DCs), Tregs, MDSCs, and
tumor-associated macrophages (TAMs).
Dr. Hans Schreiber discussed the role of stromal cells in
cross-presenting tumor antigens as a means of protecting
from cancer relapse. In particular, antigen loss variant-
tumor cells can be eliminated as bystanders as a secondary
effect of destruction of the stroma that supports them,
provided adequate levels of tumor antigen are available for
stromal cross-presentation [8]. Furthermore, treating with
radiation or chemotherapy releases sufficient quantities of
tumor antigen to sensitize stromal cells for destruction by
CD8+ cytotoxic T lymphocytes [9].
Dr. David Munn discussed metabolic immunoregulatory
pathways that promote suppression in the tumor micro-
environment. One example is the IDO pathway. Within
the tumor stroma, IDO is expressed mostly by DCs and
TAMs, and is also highly expressed by Tregs within tumor
draining lymph nodes [10]. The natural role of IDO is to
promote tolerance to self-antigens, and within the tumor
microenvironment, this negative regulator serves to in-
hibit local immune activation [11]. Dr. Munn’s work
demonstrated that the expression of IDO by stromal cells,
which activates the general control non-depressible 2
(GCN2)-kinase-dependent stress response, can directly
induce anergy in effector T cells while causing concomi-
tant maturation of functionally quiescent Tregs [12]. This
creates a double whammy for tumor immunity. Down-
stream IDO metabolites can also induce the secretion of
pro-tumorigenic growth factors as well [13].
In addition to IDO, the metabolic enzyme arginase
(ARG) produced by MSDCs can also promote tumor
escape. Dr. Vincenzo Bronte discussed the toleragenic
environment in the spleen, where many immature MDSCs
are recruited. These CD11b+/Gr-1int cells are directed to
the spleen by signaling through chemokine receptor
type 2 (CCR2 or CD192) and its ligand chemokine ligand
2 (CCL2, also called monocyte chemotactic protein-1
(MCP-1)). Once in the marginal zone of the spleen,
these “super-suppressors” induce inactivation of CD8+
effector T cells through cross-presentation. Multiple
chemotherapy drugs, including 5-Fluorouracil (5-FU) and
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Gemcitabine, were able to abrogate the negative influence of
these MDSCS. Dr. Bronte’s group also showed that MDSCs
and CD8+ central memory T cells occupy the same niche in
the spleen, and that this niche could be emptied for T cells
by treating with 5-FU prior to adoptive cell transfer [14].
In his presentation, Dr. Thomas Gajewski showed that
about one third of human melanomas are T cell rich
[15], with this “inflamed” phenotype driven by type I IFN
signaling and CD8α DCs [16], whereas the remainder are
T cell poor [15]. This differential phenotype may be deter-
mined by tumor variability at the somatic level (driver
oncogenes), the genetic level (type I IFN signaling), or
the environmental level (exposure to microbes). In pre-
clinical models, Dr. Gajewski showed that tumor DNA
taken up by DCs induced the secretion of interferon-β
(IFN-β) through interferon regulatory factor-3 (IRF-3)
and stimulator of interferon genes (STING)-dependent
pathways. This DC-based innate sensing of the tumor
resulted in CD8+ T cell priming, interferon gamma (IFN-γ)
production, and T cell recruitment to the tumor site.
Highlighting the complexity of melanoma-specific tumor
immunity, a subgroup of melanoma patients with tumors
characterized by a similar “inflamed” gene signature and
increased T cell infiltration that did not regress developed
high levels of expression of the negative regulatory factors
PDL-1, IDO, and forkhead box P3 (FoxP3). In addition,
some tumor infiltrating CD8+ T cells became anergic, with
increased expression of early growth factor response gene
2 (Egr2) driving the expression of anergic markers like
lymphocyte activation gene-3 (LAG-3) and cytotoxic and
regulatory T cell molecule (CRTAM) [17].
Dr. Pierre Coulie’s presentation examined the functional
status of T cells in subcutaneous melanoma metastases.
This revealed an inflammatory, T helper type 1 gene sig-
nature associated with an increase in activated, IFN-γ-
producing T cells within the tumor by gene expression
profiling and IHC. He also demonstrated that 15-20% of
melanoma metastases were accompanied by the forma-
tion of active lymphoid aggregates with evidence of both
germinal center formation and antibody affinity matur-
ation, indicating the presence of an active adaptive immune
response at these sites [18]. Some of these metastases con-
tain T cells and others do not. For some of those that do,
there was a lack of cytotoxic T lymphocyte (CTL) killing
within the tumor. Thus, TILs may also demonstrate dys-
functional killing capacity that allows the tumor to escape
spontaneous rejection by T cells.
In summary, distinct components of the tumor micro-
environment can suppress active antitumor T cell re-
sponses in multiple ways. Endothelial cells may present
a barrier to T cell infiltration, the expression of immu-
noregulatory molecules such as PDL-1 on tumor cells,
IDO by antigen presenting cells, and ARG by MDSCs
can blunt the CD8+ T cell response, and FoxP3+ Tregs
can inhibit T cell activity. Finally, dysfunctional or anergic
CD8+ T cells may demonstrate an intrinsic decrease in
killing capacity, in part through increased expression of
both LAG-3 and Egr-2.
Reprogramming the tumor microenvironment to
promote tumor regression
Despite the many immunosuppressive mechanisms that
blunt productive immune responses, it is clear that the
presence of immune cell infiltrates are associated with
improved survival and response to therapy in some patients.
These observations suggest that there are some inherent
differences in the immune response that promote tumor
progression in some while promoting tumor regression
in others. They also imply that the tumor microenviron-
ment represents a therapeutic target that can be manipu-
lated to promote tumor regression in more patients.
Dr. Samuel Silverstein demonstrated that successful tumor
eradication is directly related to the concentration of
cytolytically active CD8+ T cells that are present in the
tumor. He showed that there is a critical concentration of
T cells necessary to halt tumor growth. At this critical
threshold, the rate of tumor clearance is equal to the rate
of tumor growth [19]. Furthermore, effective tumor clear-
ance could only be achieved when the concentration of
cytolytically active antigen-specific T cells rises above the
critical concentration threshold. He went on to demon-
strate that not all intratumoral antigen-specific T cells
are cytolytically active, and that exposure to antigen
alone increased T cell proliferation without increasing
cytolytic activity. Furthermore, an increase in cytolytic
activity was only achieved by exposure to antigen in the
presence of adjuvant. His studies elegantly demonstrate
that it is necessary to consider the concentration, inherent
cytolytic capacity, and environmental context of intra-
tumoral T cells in the design of immunotherapies.
One strategy for increasing the presence of cytolytically
active, antigen-specific T cells in the tumor is through the
adoptive transfer of T cells genetically engineered to force
the expression of tumor-antigen specific T cell receptors.
Dr. Laurence Cooper shared data demonstrating genetic
approaches to produce clinical grade high affinity T cells
engineered to express antigen specific surface receptors
that allow the recognition of antigen independent of major
histocompatibility complex (MHC). This can be achieved
by genetically editing CD19-specific chimeric antigen
receptor (CAR) T cells to eliminate expression of the
endogenous αβ T-cell receptor (TCR) without compromis-
ing CAR-dependent effector functions. Genetically modi-
fied T cells were generated using the Sleeping Beauty
system to stably introduce the CD19-specific chimeric
antigen receptor with subsequent permanent deletion of
α/β TCR chains with zinc finger nucleases. Preclinical ani-
mal studies using these genetically modified T cells have
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shown success in targeting CD19 on B cells in hemato-
poietic malignancies [20], and this approach is currently
in clinical testing.
The dynamic interplay between immune cells and tumor
cells within the tumor microenvironment rests on a multi-
tude of negative immunoregulatory molecules that can
be targeted for therapy. Cytokines, such as TGF-β, ac-
tively secreted in the tumor microenvironment blunt
inflammatory reactions induced by T cells upon TCR
engagement, resulting in upregulation of programmed
cell death-1 (PD-1) on the T cell surface. PD-1 interacts
with tumor-associated PDL-1 to inhibit T cell activity.
Dr. Drew Pardoll reported data testing the clinical use of
a monoclonal antibody specific for PD-1 to block signals
that shut T cells down, thereby promoting T cell-mediated
tumor regression [21]. The results were striking, with ob-
jective response rates of 18-25% in renal cell carcinoma,
melanoma, and non-small cell lung cancer (NSCLC). In
addition, many patients had prolonged stable disease
lasting over one year. Some patients with high levels of
PDL-1 expression at the tumor site had better responses
to anti-PD-1 therapy than those with tumors who expressed
little to no PDL-1, suggested that PDL-1 could represent
a marker that predicts response to therapy. Two add-
itional observations emerged. First, the trafficking of
IFN-γ-secreting T cells to the tumor site induces PDL-1
expression by the tumor, resulting in adaptive immune
resistance [22]. Additionally, the investigators observed
that a few patients with NSCLC previously treated with
5-azacytidine and entinostat had a marked response to
subsequent anti-PD-1 therapy. They demonstrated that
the epigenetic therapy induced PDL-1 expression at the
tumor site in these responding patients, likely through
de-methylation of the PDL-1 gene locus. Thus, epigenetic
modulation is thought to have rendered the tumors more
responsive to anti-PD-1 therapy [23]. Dr. Samir Khlief
presented preclinical modeling of combination therapy
with cyclophosphamide (CY), a vaccine specific for hu-
man papilloma virus (HPV) E7, and anti-PD-1 antibody.
This combination therapy resulted in an increase in CD8+
T cells in responders. Anti-PD-1 antibody prolonged the
inhibition of FoxP3+ Tregs by CY, and synergistically
decreased the number of FoxP3+ Tregs within the
spleen and the tumor microenvironment [24]. Similar
studies were carried out combining vaccine and CY with
B7-DC-Ig (PDL-2). Here, B7-DC-Ig resulted in a signifi-
cant decrease in the level of PD-1high CD4+ T cells
(enriched for Tregs) within the tumor. Treatment with
B7-DC-Ig also led to a decrease in exhausted PD-1high
CD8+ T cells, tipping the balance toward functional PD-1low
CD8+ T cells. Together, these clinical and preclinical
studies illustrate the promise of targeting distinct regu-
latory pathways to enhance the efficacy of current im-
munotherapies [25].
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is also
a well-established immunologic checkpoint molecule.
Dr. Antoni Ribas presented data demonstrating that
ipilimumab, a CTLA-4-specific blocking antibody, induces
a dense infiltrate of CD8+ TILs within the tumor independ-
ent of clinical response, where about half the patients with
disease progression had immune infiltrates in their tumors.
Differences in the quantity, function, or physical loca-
tion of the T cells did not account for clinical response.
Interestingly, analysis of Ki67 expression by TILs and
whole body imaging by positron emission tomography
(PET) indicated that T cell proliferation in response to
therapy occurred in the spleen and not at the tumor site.
These data suggest that multiple pathways may require
manipulation in order to achieve tumor regression, where
one signal promotes the migration of T cells into the
tumor, and the second promotes T cell cytotoxicity at the
tumor site [26].
An emerging concept is that signaling pathways acti-
vated in malignant cells that are essential to support tumor
proliferation and survival may act in part through the
immune system. Dr. Dean Felsher discussed the concept
of “oncogene addiction”, where oncogenes such as MYC
are an absolute requirement for tumor growth. Onco-
genic proteins that represent the linchpin of tumor
growth and progression can be very effectively targeted
to induce cellular senescence and promote tumor re-
gression [27]. Notably, Dr. Felsher and his colleagues
found that inhibition of oncogene driven cell growth is
dependent on the presence of an active immune response,
specifically cytokine-secreting CD4+ T cells [28].
Cells of the innate immune system may also provide
convenient cellular targets to boost the local anti-tumor
response. Dr. Phillipe Bousso presented imaging studies
using intravital multiphoton microscopy to visualize
natural killer (NK) cell dynamics within tumors. NK cells
normally recognize stress ligands on tumor cells via
natural killer group 2, member D (NKG2D) receptors.
Upon recognition of NKG2D ligands, such as Rae-1β,
NK cells attach transiently to tumor cells and induce
apoptosis, visualized in Dr. Bousso’s studies with the use of
fluorescence resonance energy transfer (FRET) combined
with differential staining of NK cells [29]. This produces
color changes within tumor cells containing activated
caspase 3. The interaction between NK cells and tumor cell
targets was prolonged with the addition of tumor-specific
monoclonal antibodies targeting CD4, which is expressed
on the surface of the murine lymphoma cell line EG7.
CD4-specific antibodies themselves engaged Fc receptors
on NK cells, prolonging cell contact without enhancing
degranulation [30].
An imbalance of effector cells to regulatory cells within
the tumor microenvironment also plays a key role in
cancer persistence in the host. A variety of therapeutic
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strategies aim to correct this imbalance, thereby redirecting
the immune cells in the tumor towards a productive im-
mune response. Dr. Thomas-Oliver Kleen presented a
novel PCR-based method for measuring and monitoring
changes in the effector T cell:Treg balance through the
use of epigenetic immune cell markers. Using this highly
sensitive method to analyze 616 samples from breast,
ovarian, and colorectal cancers, Dr. Kleen showed that
the intrinsic CD3+/FoxP3+ T cell ratio is unfavorable in
a variety of tumor types (unpublished data).
Another imbalance can be found between T helper type
17 (Th17) cells and Tregs. Dr. Weiping Zou discussed the
importance of manipulating this balance to favor Th17
cells and promote long-term immunity in an adoptive
transfer model using NOD/SCID mice implanted with hu-
man ovarian cancer xenografts. Only simultaneous trans-
fer of both Th17 and CD8+ T cells produced effective
tumor clearance. Gene expression analysis revealed that
Th17 cells show increased expression of stem cell genes,
such as Notch, and show an increased resistance to apop-
tosis. It is thought that the persistence of these Th17 cells
within the tumor microenvironment is essential for the
production of long lasting immunity. Dr. Zou also showed
data that pointed to a role for MDSCs in promoting
tumor persistence through increasing ovarian cancer cell
stemness. His data showed that MDSCs induced the
expression of microRNA101, which targets the Notch
co-repressor C terminal binding protein 2 (CtBP2). This
ultimately resulted in a derepression of CtBP2 target genes
to increase the stemness and persistence of ovarian cancer
cells [31].
Dr. Nicholas Restifo proposed a potential therapeutic
solution for the presence of MDSCs. By modifying T
cells to secrete IL-12 and using these T cells in adoptive
cell therapy, Dr. Restifo’s lab was able to show enhanced
anti-tumor immunity dependent on the cross presenta-
tion of tumor antigen and the production of IFN-γ by
CD8+ T cells in vivo [32]. In these experiments, pmel-1
CD8+ T cells, which express a transgenic TCR specific
for the melanoma-associated antigen, gp100, were trans-
duced to express high levels of IL-12. Treatment of B16
melanoma tumor bearing mice by adoptive transfer of
these cells led to increase in CD8+ T cell infiltration.
Genetic analysis of the tumors showed an increase in an
inflammatory gene signature with a marked increase in
genes associated with antigen presentation and processing.
Further cellular analysis of the tumors by flow cytometry
indicated an increase in the number of CD11b+ cells bear-
ing the IL-12 receptor. Additionally, flow sorting followed
by real time PCR (rtPCR) of these CD11b+ myeloid cells
indicated programmatic changes indicative of an increased
inflammatory response through an increase in IFN-γ.
Functional analysis of the myeloid cells from the tumor
showed a marked increase in their ability to stimulate T
cell proliferation [33]. These experiments demonstrate
that tumor-suppressive mechanisms can be overturned to
support potent antitumor immunity, where inflammation
driven by IFN-γ and its targets reprograms the immune
cells within the tumor microenvironment to successfully
induce tumor regression.
When designing effective immunotherapies, it may be
equally important to consider not only the tumor micro-
environment before and after vaccination, but also to con-
sider the microenvironment of immune priming at the
vaccine site itself. Whole cell granulocyte-macrophage
colony-stimulating factor (GM-CSF)-secreting vaccines
(GVAX) have been used in pre-clinical modeling and clin-
ical trials to treat a variety of both solid and hematologic
malignancies. Dr. Glen Dranoff described his findings elu-
cidating the dual role of GM-CSF in immune protection
and immune tolerance. The context in which antigen
presenting cells were exposed to GM-CSF at the site of
immune priming greatly influenced the resulting immune
response within the tumor microenvironment. Initial
in vitro studies showed when GM-CSF-proficient APCs
encountered apoptotic cells in the presence of milk fat
globule-EGF factor-8 protein (MFG-E8, or lactadherin),
the secretion of TGF-β and CCL22 was increased com-
pared to GM-CSF-deficient APCs. In vivo, these factors
support the recruitment of Tregs, blunting the immune
response. Translating these studies in vivo using a therapy
model with B16 mice, when a GM-CSF vaccine was
engineered to express a dominant negative mutant of
MFG-E8 (RGE), vaccine efficacy was restored and tumor-
free survival was increased. Abrogating the influence of
MFG-E8 enhanced the phagocytic capacity of CD11b+
myeloid cells, thus increasing both the CD8+/ FoxP3+ T
effector cell ratio and humoral immunity [34]. In addition,
MFG-E8 blockade in combination with chemotherapy,
molecularly targeted therapy, and radiation induced the
destruction of various tumor types in preclinical models.
These combination treatments provoke extensive tumor
cell apoptosis, leading to highly effective cross-presentation
of dying tumor cell to DCs [35].
Dr. Dranoff also discussed an innovative approach to in-
tensifying tumor immunity through improving the in vivo
delivery of immunomodulating agents at the time of
immune priming. Porous polymer scaffolds containing
GM-CSF, the toll-like receptor (TLR) agonist CpG, and
tumor cell lysates were implanted subcutaneously in mice.
These “immunologically charged” scaffolds enhanced DC
maturation, decreased suppressive cytokines such as
IL-10 and TGFβ, and increased Th1-cytokines. This
novel polymer-based delivery prolongs immune priming
through slow metabolism of the polymer into lactic acid
with the gradual, steady release of its contents, thereby creat-
ing long-lasting anti-tumor immunity. Thus, engineered scaf-
folds might provide a means to enhance tumor selectivity,
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both promoting a durable immune response while simul-
taneously reducing the risk of inflammatory toxicity [36].
Tumor specific immune responses may be measured
directly at the tumor site, or indirectly within the peripheral
blood. Dr. Mary Disis reported the presence of auto-
immune serologic response signatures that may be predict-
ive of therapeutic response to vaccination in breast cancer.
Retrospective data analysis of phase 1 and phase 2 clinical
trials using HER-2 peptide vaccine given with adjuvant
GM-CSF demonstrated an association between epitope
spreading and survival [37,38]. Serological analysis was
performed using serological analysis of recombinant
tumor cDNA expression libraries (SEREX) comparing
antibody response signatures from long term survivors
who underwent epitope spreading to non-responders.
Here, an autoantibody signature predicted survival. Per-
ipheral blood was also analyzed by human GeneChip
microarray, revealing a type 1 IFN gene signature detect-
able within the peripheral blood of responders (unpub-
lished data). Dr. Disis went on to hypothesize that the
development of autoantibodies to nucleosome-, DNA-, or
RNA bound proteins may increase the uptake of these
proteins by DCs. When released inside the cell, they
may propagate a type 1 interferon response through
toll-like receptor (TLR) signaling, thereby augmenting
cross-priming and epitope spreading. Future studies aim
to further characterize these immune response signatures
in order to define a signature of immune-mediated tumor
rejection that is independent of the therapeutic modality.
Profiling the cytokine milieu within the tumor
microenvironment may also predict disease outcome.
Dr. Helen K. Angell showed that interleukin-15 (IL-15) is
an important predictor of the metastatic potential of pri-
mary colorectal cancers after surgery. The presence of
deletions in the IL-15 gene in patients strongly corre-
lated with increased metastasis, whereas high IL-15 ex-
pression correlated with increased disease free survival.
Additionally, the presence of high levels of IL-15 were
correlated with increased numbers of Ki67+ CD3+ T cells
and CD20+ B cells in patients with longer survival. Digital
imaging analysis revealed proliferating cells mostly within
the invasive margin of the tumors (unpublished data).
Clinical strategies for integrative
immunotherapies: inciting lasting immunity in the
tumor microenvironment
Preclinical studies elucidating the dynamic host-tumor
cell interactions within the microenvironment have laid
a solid foundation for the development of novel immuno-
therapies that integrate agents specific for immunoregula-
tory pathways with agents that generate increased numbers
of antigen-specific T and B cells. The first clinical interven-
tions that aim to target the microenvironment to enhance
tumor immunity are under active evaluation in the clinic.
Dr. Brian Rini discussed the use of the antiangiogenic
molecule sunitinib for the treatment of renal cell carcin-
oma (RCC). In addition to antiangiogenic activity, sunitinib
can decrease splenic MDSCs and increase intratumoral
CD3+ IFN-γ-secreting T cells in preclinical models. In
metastatic RCC patients, sunitinib reduced both MDSC
and Tregs in the peripheral blood, and increased IFN-γ
secretion by T cells [39]. These observations led to the
design of a trial to define how sunitinib might alter the
tumor microenvironment in RCC patients. In this trial,
neoadjuvant sunitinib treatment resulted in a decrease
in CD33+HLADR- MDSCs and a concomitant increase
in CD3+ IFN-γ-secreting T cells in a small subset of pa-
tients. Patients with no notable changes in MDSC num-
ber displayed upregulation of the pro-angiogenic matrix
metalloproteinases MMP8 and MMP9, and interleukin
8 (IL-8) (unpublished data). The effect of these distinct
tumor responses to sunitinib treatment on patient out-
come or acquired drug resistance to sunitinib is not
yet known. Future studies will combine sunitinib with
cyclophosphamide and IMA901, a vaccine containing
multiple RCC associated peptides. Early data shows that
lower baseline MSDC levels are associated with longer
overall survival in these patients [40].
Dr. Dimitry Gabrilovich discussed regulation of the im-
mune response through the inhibition of MDSCs. He has
demonstrated that all-trans retinoic acid (ATRA) can re-
duce the number of CD11b+CD14+CD33+ cells in small
cell lung carcinoma (SCLC) patients. He hypothesized that
removing suppressive myeloid populations could enhance
the efficacy of vaccination with p53-specific peptide vac-
cines, and reported a clinical study testing this concept.
Early results revealed that combination therapy increased
both p53-specific immune responses and the number of
granzyme B+ CD8+ T cells in the blood (unpublished
data). Further analyses will determine if this combin-
ation immunotherapy will provide an overall clinical
benefit to patients suffering from SCLC.
Dr. Ivan Borrello demonstrated a novel activity for
phosphodiesterase type 5 (PDE5) inhibitors in decreasing
the production of inducible nitric oxide (iNOS), arginase,
and IL-4Rα by MDSCs [41]. In a neoadjuvant trial, he
showed that Tadalafil, a PDE5 inhibitor, could effectively
target MSDCs and potentiate immune responses in pa-
tients with head and neck squamous cell carcinoma
(HNSCC) 2 weeks prior to surgery or radiation therapy.
Patients receiving the PDE5 inhibitor showed a significant
increase in both candida-specific delayed type hypersensi-
tivity (DTH) responses and T cell expansion to CD3 plus
CD28 stimulation, and a decrease in MDSC compared to
the patients receiving placebo. These data reveal a novel
immunoregulatory activity associated with PDE5 inhib-
ition. There also appeared to be an enhanced number of
CD69+CD4+ T cells with no corresponding increase in
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CD8+ T cells. Lastly, PDE5 inhibition enhanced tumor-
specific T cell responses when patient-derived DCs were
pulsed with tumor lysate and co-cultured with patient T
cells (unpublished data). These data therefore demon-
strated the ability of PDE5 to augment the global immune
response in HNSCC by decreasing MDSCs and increasing
T cell proliferation. Future studies aim to examine the
combination of a PDE5 inhibitor with chemotherapy and
vaccine to determine the efficacy in enhancing the im-
mune response through modulation of MDSCs.
Combination immunotherapy trials designed to test
vaccines in sequence with cyclophosphamide (CY) to miti-
gate the influence of Tregs, or in combination with CY
and a therapeutic monoclonal antibody (Trastuzumab
(Herceptin)), to enhance antigen processing and presenta-
tion were discussed by Dr. Leisha Emens. Here, a HER2-
expressing whole cell GM-CSF secreting breast tumor
vaccine was tested in sequence with a range of low, im-
mune modulating doses of CY and doxorubicin (DOX) in
patients with metastatic breast cancer. This study demon-
strated that 200mg/m2 CY and 35mg/m2 DOX were able
to maximally induce HER2-specific antibody responses,
while maintaining the HER-2-specific DTH response. The
optimal dose of CY tested was able to decrease peripheral
Tregs without decreasing effector T cell populations [42].
In a second trial, low dose CY (300 mg/m2) was sequenced
with vaccine in the setting of standard weekly trastuzumab
therapy for HER-2+ metastatic breast cancer. Here, about
50% of patients showed a clinical benefit at 6 months
following treatment, and about 35% showed a clinical
benefit at 1 year following treatment (unpublished data).
This multi-agent immunotherapy is now being tested
for use in HER2-negative patients, where a single dose
of Trastuzumab is given with CY at the time of immune
priming. These studies aim to determine optimal immu-
notherapeutic treatment strategies to enhance the im-
mune response and promote tumor regression in distinct
breast cancer subtypes.
The immunoscore
While promising immunotherapies are being tested in
clinical trials, it remains unclear how to select the patients
most likely to respond. A hurdle in predicting potential re-
sponders to immunotherapy is that current tumor staging
does not take the immune context of the tumor into ac-
count. Incorporating immune cell analyses into the stand-
ard staging based on tumor size, lymph node status, and
metastatic disease (TNM stage) may better select those
patients who may benefit from immunotherapy as well as
improve patient stratification and prognosis for standard
cancer therapy.
Dr. Alessandro Lugli discussed the importance of immune
cells as prognostic markers in colorectal cancer (CRC). He
showed that CD8 and receptor for hyaluronan-mediated
motility (RHAMM or CD168) are important biomarkers
in rectal cancer, where lack of CD8+ TIL and high levels
of RHAMM led to lower survival independent of disease
stage [43]. In particular, patients with T1 and T2 tumors
that express high levels of RHAMM but contain no T cells
have a 5-year cancer-specific survival rate similar to pa-
tients with T3 or T4 cancers. In CRC CD8+CD45RO+
effector memory cells are a valuable predictor of favor-
able outcome in early stage colon cancer [44]. Further-
more, the absence of CD8+ T cells predicts shorter
survival in stage II colon cancer patients. In particular,
urokinase-type plasminogen activator (uPA) positive, T3
tumors without CD8+ cells showed no difference in sur-
vival compared to T4 patients [45]. This is especially sig-
nificant for stage II CRC patients because currently they
are not recommended for adjuvant therapy, and, these
data imply that T3 patients with CD8- uPA+ lymph node
negative tumors may derive a survival benefit from adju-
vant therapy. These data illustrate the potential value of
immune cells as predictors of disease-free survival, and
possibly therapeutic response, in CRC.
Dr. Jerome Galon has led a major effort to promote
greater understanding of the importance of TILs as a
powerful predictor of patient survival. He and his col-
leagues have shown that the type, density, and location
of immune cells within the tumor microenvironment of
CRC have prognostic value that is superior to and inde-
pendent of the TNM classification. The presence of CD8+
T cells in particular are powerful predictors of decreased
local recurrence, and improved disease-free survival and
overall survival in patients with CRC, as demonstrated in
a large multivariate COX proportional hazard analysis
of 499 patients with Stage I, II, and III CRC. These studies
resulting in a proposed Immunoscore based on CD3 and
CD8 staining within the tumor and at the invasive margin
of CRC [46,47].
Developing this further, Dr. Galon is on the SITC
Taskforce steering committee that aims to validate the
Immunoscore and promote its use as one of the stand-
ard histopathological assessments at the time of cancer
diagnosis. Specifically, the Taskforce aims to validate
the Immunoscore as an independent prognostic marker
for CRC and potentially as a new classification of CRC.
The task force has organized 22 centers in 16 countries
to undertake this validation, with a centrally managed
data cloud that will allow participating centers to
share and store digital images [48]. Current studies are
also underway evaluating whether the CD3 and CD8
Immunoscore or some other combination of immune
markers may serve as a prognostic marker in at least
18 other cancers. Finally, studies are underway to in-
vestigate whether a blood-based Immunoscore may be
of value for situations where tissue is inaccessible or
not available.
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The Immunoscore provides a way for clinicians to
have a “sneak peek” at the immune status within tumor
microenvironment to help determine treatment strategies.
Determining individual patient’s Immunoscores may allow
clinicians to better predict survival and therapeutic re-
sponse. Dr. Bernard Fox emphasized the importance
of implementing the Immunoscore to facilitate the strati-
fication of patients into potential responders (T cell-rich)
and nonresponders (T cell-poor) to currently available
immunotherapies, and possibly other therapies as well.
This invaluable information may allow T cell-poor patients
to be treated first by therapies that will stimulate an im-
mune response at the tumor site. If that is not possible,
it may indicate a need for the development of a second
generation of immunotherapeutics that are more cap-
able of igniting the immune response via new, improved
vaccination strategies and/or multiple immune check-
point blockade strategies to overcome tumor resistance
and increase the efficacy of immunotherapies in these
patients.
Dr. Francesco Marincola concluded the workshop by
discussing the immune-mediated destruction of tumors,
and highlighted the concept of prognostic, predictive, and
mechanistic immune signatures along the continuum of
immune surveillance. He emphasized the need for the
application of multivariate analyses to adequately powered
clinical data sets to assess immune responsiveness, and
how it is influenced by the host genetic background as well
as tumor intrinsic and environmental factors. He reviewed
data showing that genetic signatures can predict melan-
oma tumor regression post-immunotherapy, and that a
genetic mutation in CCR5 at the host level, specifically
the delta-32 mutation, is associated with shorter disease-
specific survival [49]. In melanoma, only when delta-32
mutations are considered and both CCR5 expression and
CXCR3 expression are analyzed can these genes signifi-
cantly predict complete responders, indicated by an odds
ratio of greater than 6 [50].
Conclusions
The research presented at the 2012 SITC Workshop
highlighted a rapidly growing appreciation for the complex-
ities of the tumor microenvironment, and how they might
be manipulated therapeutically to promote or even provoke
effective tumor immunity. Importantly, accurately profiling
the immunobiology of the tumor microenvironment—and
standardizing an Immunoscore—will better define prognosis
and response to both immune-based and standard cancer
therapies. The future of immunotherapy will almost cer-
tainly involve integrative strategies that target multiple im-
mune modulating networks and effector cells to not only to
amplify existing immune responses in patients predicted to
be immunologic responders, but also to stimulate new im-
munity that can be subsequently amplified in patients
predicted to be immunologic nonresponders. Using in-
tegrated, sequential combination treatment strategies
matched to both the genetics and immunobiology of a
patient’s tumor will make personalized immunotherapy
a reality, leading to increased cancer cure rates and ul-
timately effective cancer prevention strategies.
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